Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3446-3459 ◽  
Author(s):  
Michael C. Singer ◽  
Francis Marchal ◽  
Peter Angelos ◽  
Vic Bernet ◽  
Laura Boucai ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Salivary Gland ◽  
Head And Neck ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Consensus Statement ◽  
Endocrine Surgery

scholarly journals A Randomized Controlled Trial for the Effectiveness of Aromatherapy in Decreasing Salivary Gland Damage following Radioactive Iodine Therapy for Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Michihiro Nakayama ◽  
Atsutaka Okizaki ◽  
Koji Takahashi
Keyword(s):  
Thyroid Cancer ◽  
Salivary Gland ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Control Group ◽  
Parotid Glands ◽  
Before And After ◽  
Group A ◽  
Gland Function ◽  
Group B

Objective. The aim of this study was to investigate effects of aromatherapy in decreasing salivary gland damage for patients undergoing radioactive iodine (RAI) therapy with differentiated thyroid cancer (DTC). Materials and Methods. The subjects were 71 patients with DTC. They were divided into aromatherapy group (group A, n=35) and a control group (group B, n=36). We blended 1.0 mL of lemon and 0.5 mL of ginger essential oils. The patients in the inhalation aromatherapy group inhaled this blend oil and those in the control group inhaled distilled water as placebo for 10 min during admission. We statistically compared salivary gland function before and after treatment between groups A and B. Results. In comparison with group B, the rate of change of the accumulation rate was significantly higher in the parotid glands and submandibular glands of group A (P<0.05). In comparison with group B, a significant increase in rate of secretion change before and after treatment was noted in the bilateral parotid glands in group A (P<0.05). Conclusion. Because an amelioration of salivary gland function was observed in the present study, our results suggest the efficacy of aromatherapy in the prevention of treatment-related salivary gland disorder. This trial is registered with UMIN Clinical Trial Registry: UMIN000013968.

scholarly journals Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer

Oral Oncology ◽  
2021 ◽  
Vol 121 ◽  
pp. 105477
Author(s):  
Andrée Boucher ◽  
Shereen Ezzat ◽  
Sebastien Hotte ◽  
Irina Rachinsky ◽  
Murali Rajaraman ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Consensus Statement

scholarly journals Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Pablo Florenzano ◽  
Francisco J. Guarda ◽  
Rodrigo Jaimovich ◽  
Nicolás Droppelmann ◽  
Hernán González ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Salivary Gland ◽  
Adverse Effects ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Dry Mouth ◽  
Low Doses ◽  
Periorbital Edema ◽  
Risk Patients ◽  
Taste Disorders

Context. Radioiodine (RAI) administration has adverse effects in patients treated for thyroid cancer (DTC), but there is scarce information regarding their intensity and duration.Objective. To evaluate frequency and intensity of early and late RAI-related symptoms in patients with DTC.Design. Observational prospective study.Patients. DTC patients who underwent thyroidectomy, with or without RAI.Measurements. Patients answered 2 surveys: (1) from 0 to 6 months and (2) between 6 and 18 months after initial treatment.Results. 110 patients answered the first survey and 61 both. Nearly 80 percent received RAI. Among early symptoms, periorbital edema, excessive tearing, salivary gland disturbances, dry mouth, taste disorders, and nausea were more frequent and intense among RAI patients. Regarding late symptoms, periorbital edema, salivary gland pain and swelling, and dry mouth were more frequent and intense in RAI patients. Frequency and intensity of adverse effects were not different between low and high RAI doses (50 versus ≥100 mCi).Conclusion. RAI-related symptoms are frequent and usually persist after 6 months of administration, even when low doses are given. This finding must be considered when deciding RAI administration, especially in low risk patients, among whom RAI benefit is controversial.

scholarly journals Management of invasive well-differentiated thyroid cancer: An American head and neck society consensus statement: AHNS consensus statement

Head & Neck ◽  
2014 ◽  
pp. n/a-n/a ◽  
Author(s):  
Maisie L. Shindo ◽  
Salvatore M. Caruana ◽  
Emad Kandil ◽  
Judith C. McCaffrey ◽  
Lisa A. Orloff ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Head And Neck ◽  
Differentiated Thyroid Cancer ◽  
Consensus Statement ◽  
Well Differentiated
Sign in / Sign up

Export Citation Format

Share Document